Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies

Shots:

• Wugen to get exclusive & IPR rights for CAR-T Technologies developed by Washington University
• The focus of the agreement is to develop and commercialize novel CAR-T therapies to treat blood cancer
• The novel CAR-T therapy platform including fratricide-resistant “off-the-shelf” system, targeting CD7+ T cell malignancies

Click here to read full press release/ article | Ref: PRNewswire | Image: The Business Journals